- GLP-1 (glucagon-like peptide-1) analogues are injectable drugs used primarily for the treatment of type 2 diabetes and obesity, improving blood sugar control and aiding in weight loss by mimicking the GLP-1 hormone
- The market growth is significantly driven by the increasing global prevalence of obesity and type 2 diabetes, along with growing awareness of the benefits of GLP-1 analogues in weight management
- North America is expected to lead the GLP-1 analogues market with with an estimated market share of over 76.05%, due to high obesity rates, robust healthcare systems, and early adoption of advanced therapies
- Asia-Pacific is projected to witness the fastest growth owing to rising diabetic population, healthcare access improvements, and expanding awareness of chronic disease management
- Ozempic segment is expected to dominate the market with a market share of 34.67% due to its proven efficacy in lowering HbA1c levels and promoting significant weight loss in patients with type 2 diabetes. Its once-weekly dosing improves patient adherence, while strong clinical outcomes and widespread physician adoption further support its market leadership
